SCYNEXIS, Inc. Unrealized Gain (Loss) on Derivatives
SCYNEXIS, Inc. (SCYX) reported Unrealized Gain (Loss) on Derivatives of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2017-03-13
- SCYNEXIS, Inc. unrealized gain (loss) on derivatives for fiscal 2016 was $0.00.
- SCYNEXIS, Inc. unrealized gain (loss) on derivatives for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- SCYNEXIS, Inc. unrealized gain (loss) on derivatives for fiscal 2014 was $10.08M.
| Period end | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-13 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-13 |
| 2014-12-31 | $10.08M 10-K · filed 2017-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |